Cargando…

Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease

BACKGROUND: This randomized, open-label phase 2a study investigated the safety/tolerability, pharmacokinetics, and efficacy of olorinab—a highly selective, peripherally acting, full agonist of the cannabinoid receptor 2—in patients with Crohn’s disease (CD) experiencing abdominal pain. METHODS: Elig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yacyshyn, Bruce R, Hanauer, Stephen, Klassen, Preston, English, Brett A, Stauber, Kathe, Barish, Charles F, Gilder, Kye, Turner, Stewart, Higgins, Peter D R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802051/ https://www.ncbi.nlm.nih.gov/pubmed/36777064 http://dx.doi.org/10.1093/crocol/otaa089

Ejemplares similares

Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents
por: Castro, Joel, et al.
Publicado: (2022)

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
por: Hemperly, Amy, et al.
Publicado: (2021)

Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2020)

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB(2) receptor
por: Patel, Monica, et al.
Publicado: (2023)

Capturing Structural Variants of Herpes Simplex Virus Genome in Full Length by Oxford Nanopore Sequencing
por: Saranathan, Rajagopalan, et al.
Publicado: (2022)

A novel treatment for non-melanoma skin cancer of the ear: V to Y full thickness skin graft
por: Sivyer, Graham
Publicado: (2012)

Access to biologicals in Crohn’s disease in ten European countries
por: Péntek, Márta, et al.
Publicado: (2017)

Fungal dysbiosis predicts the diagnosis of pediatric Crohn’s disease
por: El Mouzan, Mohammad I, et al.
Publicado: (2018)

A Novel Capsule Endoscopic Score for Crohn’s Disease
por: Omori, Teppei, et al.
Publicado: (2020)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn’s Disease: Is There Any Difference between Small Intestine and Colonic Lesions?
por: Matsumoto, Satohiro, et al.
Publicado: (2023)

Thiopurines are negatively associated with anthropometric parameters in pediatric Crohn’s disease
por: Gupta, Neera, et al.
Publicado: (2018)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Physical Activity in Adults With Crohn’s Disease: A Scoping Review
por: Neal, Whitney N, et al.
Publicado: (2022)

Temporal trends in the misdiagnosis rates between Crohn’s disease and intestinal tuberculosis
por: Seo, Hyungil, et al.
Publicado: (2017)

Fecal MicroRNAs Show Promise as Noninvasive Crohn’s Disease Biomarkers
por: Wohnhaas, Christian T, et al.
Publicado: (2020)

A Polymorphism in the Epstein-Barr Virus EBER2 Noncoding RNA Drives In Vivo Expansion of Latently Infected B Cells
por: Wang, Yiping, et al.
Publicado: (2022)

Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients
por: Huang, Xiao-Min, et al.
Publicado: (2023)

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients
por: Foster, Alice Jane, et al.
Publicado: (2019)

Simple pain measures reveal psycho-social pathology in patients with Crohn’s disease
por: Odes, Shmuel, et al.
Publicado: (2017)

All ileo-cecal ulcers are not Crohn’s: Changing perspectives of symptomatic ileocecal ulcers
por: Toshniwal, Jay, et al.
Publicado: (2017)

Intestinal dysbiosis in pediatric Crohn's disease patients with IL10RA mutations
por: Xue, Ai-Juan, et al.
Publicado: (2020)

Comparison of cytokine and phosphoprotein profiles in idiopathic and Crohn’s disease-related perianal fistula
por: Haddow, James B, et al.
Publicado: (2019)

Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
por: Ramos, Guilherme Piovezani, et al.
Publicado: (2021)

Oral Contraceptive Pills Are an Effective Method of Preventing Pregnancy in Women With Crohn’s Disease
por: Daoud, Nader D, et al.
Publicado: (2021)

Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn’s Disease
por: Quiros, Jose Antonio, et al.
Publicado: (2021)

Crohn’s Disease Patient Experiences and Preferences With Disease Monitoring: An International Qualitative Study
por: Rohatinsky, Noelle, et al.
Publicado: (2023)

The Impact of Crohn’s Perianal Fistula on Quality of Life: Results of an International Patient Survey
por: Spinelli, Antonino, et al.
Publicado: (2023)

Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence
por: Baillet, Pierre, et al.
Publicado: (2018)

Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota
por: Bakhshi, Zeinab, et al.
Publicado: (2020)

Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn’s Disease
por: Siegel, Corey A, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s Disease
por: George, Alvin T, et al.
Publicado: (2023)

Risk of Cancer in Patients With Crohn’s Disease 30 Years After Diagnosis (the IBSEN Study)
por: Follin-Arbelet, Benoit, et al.
Publicado: (2023)

Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
por: Takheaw, Nuchjira, et al.
Publicado: (2023)

New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists
por: Faúndez-Parraguez, Manuel, et al.
Publicado: (2021)

Docking and Molecular Dynamic Investigations of Phenylspirodrimanes as Cannabinoid Receptor-2 Agonists
por: Omar, Abdelsattar M., et al.
Publicado: (2022)

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis
por: Abraham, Bincy P, et al.
Publicado: (2022)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication
por: Adams, Lily E., et al.
Publicado: (2021)

Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease
por: Thomassin, Lucie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8a506cvforj74sgonsd4e5jnv8